Aerobic Nitroreduction by Flavoproteins: Enzyme Structure, Mechanisms and Role in Cancer Chemotherapy

Author(s): Jane V. Skelly, Richard J. Knox, Terence C. Jenkins

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 1 , Issue 3 , 2001

Become EABM
Become Reviewer
Call for Editor


NQO1 (DT-diaphorase) and its truncated isoenzyme, the metalloenzyme NQO2, can reduce quinone substrates by two-electron transfer. While NQO1 is a known detoxification enzyme, the function of NQO2 is less well understood. Both rat NQO1 and human NQO2 reductively bioactivate the dinitroarene CB 1954 to a cytotoxic product that behaves as a difunctional DNA-crosslinking species with potent anti-tumour activity, although human NQO1 is much less effective. A FMN-dependent nitroreductase from E. coli B also reduces quinones and reductively bioactivates CB 1954. However, this enzyme reduces CB 1954 to the 2- and 4-hydroxylamines in equivalent yield, whereas NQO1 and NQO2 generate only the 4-isomer. The reduction profile is a key factor in the development of anti-tumour prodrugs, where distinct delivery strategies are being evaluated: prodrug therapy, antibody-, macromolecule- and gene-directed enzyme prodrug therapy (ADEPT, MDEPT or GDEPT). The flavoprotein enzymes are explored in terms of structure and bioreduction mechanism, particularly for use in the design of novel prodrugs with potential application as chemotherapeutic agents.

Keywords: Aerobic Nitroreduction, Flavoproteins, Cancer Chemotherapy, anti-tumour prodrugs, flavoprotein enzymes, Quinone reductase type 1, Quinone reductase type 2 (NQO2)

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2001
Page: [293 - 306]
Pages: 14
DOI: 10.2174/1389557013406800
Price: $65

Article Metrics

PDF: 9